Merck advanced its succession plan for senior management, announcing that Kenneth Frazier, currently president of the Global Human Health worldwide sales and marketing division, has been elected company president by the board of directors. The promotion puts Frazier in line to succeed current chairman and CEO Richard Clark, who will continue in those roles for now. Adam Schechter, currently head of the US pharmaceutical business, was elected to succeed Frazier as president, Global Human Health. In a statement, Merck said Frazier played a key role in the integration of Schering-Plough, including maintaining sales momentum during the merger, and helped design and implement a new commercial sales model in the United States, Europe and other markets. Frazier joined Merck in 1992 and has held a number of key leadership posts, including general counsel from 1999 through 2007, first as SVP and then as EVP. In that role, Frazier was responsible for presiding over the Vioxx litigation and other legal and public affairs functions as well as The Merck Company Foundation. As president, he will lead Merck's three largest worldwide divisions: pharmaceutical and vaccine sales and marketing, research and development, and manufacturing and supply.